On May 6, 2020, Mesoblast announced that the first patients were dosed in the 300-patient randomized placebo-controlled Phase 2/3 trial in the U.S. of Mesoblast’s allogeneic cellular medicine remestemcel-L in COVID-19 infected patients with moderate to severe acute respiratory distress syndrome (ARDS) on ventilator support. The trial will include up to 30 sites across North America.